BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260615T170000
DTEND;TZID=America/New_York:20260615T183000
DTSTAMP:20260615T124518
CREATED:20260611T125809Z
LAST-MODIFIED:20260615T121138Z
UID:3071-1781542800-1781548200@lifescievents.com
SUMMARY:Humacyte\, Inc. Virtual Investor Event to Discuss Positive V012 Phase 3 Results In Which ATEV Outperformed Standard of Care In Female Dialysis Access Patients
DESCRIPTION:Join Humacyte for a virtual investor event featuring KOL Mohamad A. Hussain\, MD\, PhD\, RPVI\, FAHA\, FRCSC\, FACS (Brigham & Women’s Hospital\, Center for Surgery and Public Health\, Harvard Medical School)\, who will join company management to discuss the unmet need and current treatment landscape for hemodialysis patients with End-Stage Renal Disease (ESRD). \nThe event will provide an overview of the Company’s investigational Acellular Tissue Engineered Vessel (ATEV)\, and review positive interim clinical data from its Phase 3 V012 study. The current standard of care for providing AAV access involves connecting the patient’s artery with a vein\, known as an arteriovenous fistula or AV fistula (AVF). In a prespecified interim analysis conducted in the first 80 patients enrolled in the study\, Humacyte’s ATEV met the superiority primary endpoint after one year of follow up\, with ATEV observed to have an average of 91 more catheter-free days compared to AVF. Data from the V012 trial were presented at the Society for Vascular Surgery’s (SVS’s) Vascular Annual Meeting (VAM) and featured at the Women’s Health seminar June 11th in Boston. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/w39hs7t/.
URL:https://lifescievents.com/event/w39hs7t/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/06/Banners-14.png
END:VEVENT
END:VCALENDAR